Surmodics inc (SRDX)
Income statement / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10Sep'09
Revenue:
Total revenue

100,077

81,336

73,112

71,366

61,898

57,439

56,132

51,928

52,756

54,488

121,534

Operating costs and expenses:
Product costs

13,639

13,997

11,422

10,908

8,619

8,016

7,898

7,418

6,750

6,806

7,508

Research and development

52,885

40,973

31,817

18,498

16,165

15,550

15,079

14,143

14,005

18,972

21,179

Customer research and development

-

-

-

-

-

-

-

-

-

-

13,183

Selling, general and administrative

23,950

24,111

20,478

18,000

14,906

14,691

13,859

14,025

14,862

12,509

17,200

Acquired in-process research and development

890

7,888

-

-

-

-

-

-

-

-

3,200

Acquired intangible asset amortization

2,405

2,491

2,419

2,422

619

606

-

-

-

-

-

Contingent consideration gain

-161

675

-127

1,492

-

-

-

-

-

-

-

Acquisition transaction, integration and other costs

-

-

-

3,187

-

-

-

-

-

-

-

Restructuring charges

-

-

-

-

-

-

476

-

1,616

1,204

1,763

Claim settlement

-

-

-

-

2,500

-

-

-

-

-

-

Asset impairment charges

-

-

-

-

-

-

-

-

-

3,006

-

Total operating costs and expenses

93,608

90,135

66,009

54,507

42,809

38,863

37,312

35,586

37,233

42,497

64,033

Operating (loss) income

6,469

-8,799

7,103

16,859

19,089

18,576

18,820

16,342

15,523

11,991

57,501

Other (expense) income:
Investment income, net

1,097

851

390

63

156

238

268

540

627

1,022

1,839

Interest expense

152

-

-

-

-

-

-

-

-

-

-

Foreign exchange (loss) gain

134

239

-504

-481

-

-

-

-

-

-

-

Impairment loss on strategic investment

-

-

-

-

1,500

1,184

158

804

0

7,943

-

Gains on strategic investments and other

10

177

44

507

496

842

1,293

-

0

-

-

Other

-

-

-

-

-

-

137

228

379

314

184

Other (expense) income

1,089

1,267

-70

89

-848

-104

1,540

-36

1,006

-6,607

2,023

(Loss) income before income taxes

7,558

-7,532

7,033

16,948

18,241

18,472

20,360

16,306

16,529

5,384

59,524

Income tax benefit

-34

-3,075

3,107

6,963

6,294

6,265

5,781

6,177

5,604

4,979

21,974

Income from continuing operations

-

-

-

-

-

12,207

14,579

10,129

10,925

405

-

Loss from discontinued operations, net of income taxes

-

-

-

-

-

-176

588

1,176

-29,431

-21,494

-

Loss on sale of discontinued operations, net of income taxes

-

-

-

-

-

-

-

-1,074

0

-

-

Loss from discontinued operations

-

-

-

-

-

-176

588

102

-29,431

-21,494

-

Net income

7,592

-4,457

3,926

9,985

11,947

12,031

15,167

10,231

-18,506

-21,089

37,550

Basic income (loss) per share:
Continuing operations

-

-

-

-

-

0.90

1.01

0.58

0.63

0.02

-

Discontinued operations

-

-

-

-

-

-0.01

0.04

0.01

-1.69

-1.24

-

Basic net income per share

0.57

-0.34

0.30

0.77

0.92

0.88

1.05

0.59

-1.06

-1.21

2.15

Diluted income (loss) per share:
Continuing operations

-

-

-

-

-

0.88

0.99

0.58

0.63

0.02

-

Discontinued operations

-

-

-

-

-

-0.01

0.04

0.01

-1.69

-1.24

-

Diluted net income per share

0.55

-0.34

0.29

0.76

0.90

0.87

1.03

0.59

-1.06

-1.21

2.15

Weighted average number of shares outstanding:
Basic

13,389

13,157

13,153

12,998

13,029

13,632

14,464

17,318

17,419

17,372

17,435

Dilutive effect of outstanding stock options and non-vested stock

-

-

-

-

-

-

-

-

-

-

34

Diluted

13,779

13,157

13,389

13,219

13,289

13,876

14,731

17,431

17,462

17,380

17,469

Product Sales [Member]
Total revenue

40,219

37,953

32,790

30,999

24,925

22,798

22,506

20,742

20,150

17,364

19,333

Royalties and License Fees [Member]
Total revenue

48,458

35,424

31,787

33,203

31,763

30,277

29,774

27,445

30,385

33,843

75,464

Research, Development and Other [Member]
Total revenue

11,400

7,959

8,535

7,164

5,210

4,364

3,852

3,741

2,221

3,281

26,737